HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS

The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	STAUCH, Oliver Boris, MAHLER, Hanns-Christian, ADLER, Michael
Format:	Patent
Sprache:	eng ; hun
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention claims high dose CD20 antibody subcutaneous formulations together with hyaluronidase. Preferred antibodies are MabThera, Ocrelizumab and GA101, preferably in a dose of 120 mg/ml. The preferred hyaluronidase is Halozyme.